CTRI/2020/07/026630招募中2 期
Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ACT 12 tablet and ACT 13 dry syrup as an immunomodulator in adult Covid 19 positive patients
Mr Ghanshyam Goti0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients admitted with RT-PCR confirmed COVID-19 illness
- •Age more than 18 & less than 65 years of either sex
- •Mild to Moderately Covid 19 disease (NEWS score less than or equal to 8)
- •Signed informed consent must be obtained and documented according to national/local regulations
排除标准
- •Pregnant women
- •Breastfeeding women
- •Requiring ICU admission at screening
- •Patients above 65 years of age and below 18 Years
- •Past History of MI, Epileptic episodes
- •Any other co-morbidity (uncontrolled diabetes, severe hypertension from subject history) which
- •is at critical stage at screening
- •Any other condition by which subject proves unfit from investigator perspective
- •Not giving consent.
研究者
相似试验
尚未招募
2 期
Clinical trial of ShatPlus as an immunomodulator in adult Covid 19 positive patientsCTRI/2020/06/025999BVG Life Sciences Ltd
已完成
2 期
Evaluate Safety and Efficacy of RV Forte Capsule as an immunomodulator in adult Covid 19 positive patientsCTRI/2020/10/028568RV New Vision Healthcare Pvt Ltd60
尚未招募
2 期
Clinical trial of herbal supplement as an immunomodulator in adult Covid 19 positive patients.CTRI/2020/06/026187Mr Ghanshyam Goti
进行中（未招募）
1 期
A randomized clinical study to investigate the efficiency of a novel anti-cancer medication against neuroblastoma in children, adolescent and young adults in whom the tumor relapsed or was refractory to standard careRelapsed or refractory high risk neuroblastomaEUCTR2011-004062-15-DEniversity Hospital of Regensburg114
进行中（未招募）
1 期
A randomized clinical study to investigate the efficiency of a novel anti-cancer medication against neuroblastoma in children, adolescent and young adults in whom the tumor relapsed or was refractory to standard care.Relapsed or refractory high risk neuroblastomaEUCTR2011-004062-15-ATniversity Hospital of Regensburg114